This guide breaks down everything professionals need to know about cagrilintide administration in 2026
10.1007/s12264-018-0269-8 22 WangY.LomakinA.KanaiS.AlexR.BelliS.DonzelliM.et al (2016)
While those numbers are worth noting, theyre comparable to or lower than what is observed with Semaglutide (which saw 7-11% discontinuation across trial arms) and suggest manageable tolerability for most participants
Special tests are done to see if nearby structures are causing problems, such as a tear in the labrum or in the transverse humeral ligament
From June 2026 , you may be eligible if you have: From March 2027 , you may also be eligible if you have: For people from certain ethnic backgrounds, such as Asian, Chinese, Middle Eastern, Black African or African-Caribbean, the qualifying BMIs are 2.5 lower
Gastroenterology 160 , 24352450.e4 (2021)